• Silence dozens of interconnected essential survival genes

• Activate multiple cell death pathways simultaneously

• Kill cancer cells without observed toxicity to normal tissues

• Avoid resistance mechanisms and prevent development of resistance

Each sRNA targets and silences dozens of interconnected survival genes in a validated mechanism of action that activates multiple cell death mechanisms simultaneously. Our approach overcomes tumor heterogeneity, and overwhelms cancer resistance mechanisms as there are too many targets to overcome through mutation and too many alternative pathways required for avoidance.

Cancer cells cannot develop resistance to sRNA treatment, allowing for continued therapy or return to therapy if tumors reoccur. NUAgo’s sRNAs offer an opportunity to potentially shift cancer disease management toward a chronic-like condition with periods of complete response or tumor elimination.

Novel approach to RNAi therapeutics

Our two classes of sRNAs target multiple survival genes through RNA interference (RNAi). Class 1 sRNAs are 19nt RNAs containing a small 6nt sequence that is the active part of the sRNA. While Class 2 sRNAs are CAG trinucleotide repeats with known tumor-suppressing activity in humans and have both siRNA and miRNA-like activity.

Our initial focus is developing our first product to treat therapy resistant ovarian cancer.

Our pipeline

NUAgo therapeutics is a pre-clinical stage company combining single construct sRNAs and lipo-polyplex nanoparticle as a therapy for treatment resistant ovarian cancer (NU001) and prostate cancer (NU002).